Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from MannKind ( (MNKD) ) is now available.
On August 24, 2025, MannKind Corporation announced a definitive merger agreement to acquire scPharmaceuticals Inc. for $5.35 per share in cash and a contingent value right (CVR) worth up to $1.00 per share. This acquisition is expected to diversify and accelerate MannKind’s revenue growth, particularly with the FUROSCIX product, and strengthen its position in cardiometabolic and lung diseases. The merger is anticipated to close in the fourth quarter of 2025, subject to regulatory approvals, and aims to integrate scPharmaceuticals’ commercial capabilities into MannKind’s existing infrastructure, potentially expanding market opportunities and creating value for stakeholders.
The most recent analyst rating on (MNKD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MannKind stock, see the MNKD Stock Forecast page.
Spark’s Take on MNKD Stock
According to Spark, TipRanks’ AI Analyst, MNKD is a Neutral.
MannKind’s stock score is driven by strong earnings call insights and revenue growth, offset by financial stability concerns and a high P/E ratio. Technical indicators suggest neutral to bearish trends.
To see Spark’s full report on MNKD stock, click here.
More about MannKind
MannKind Corporation is a company that focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Their signature technologies include dry-powder formulations and inhalation devices, which offer rapid and convenient delivery of medicines to the deep lung.
Average Trading Volume: 2,983,927
Technical Sentiment Signal: Sell
Current Market Cap: $1.26B
See more insights into MNKD stock on TipRanks’ Stock Analysis page.